ClinicalTrials.gg
RecruitingNCT06095765COL BE PCIUpdated Mar 8, 2024

Colchicine in Belgium in Patients With Coronary Artery Disease After Percutaneous Coronary Intervention

A Phase 3 interventional study of Colchicine 0.5 MG Oral Tablet and Placebo in Coronary Artery Disease, sponsored by AZ Sint-Jan AV. Recruiting at 19 sites in Belgium. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2024-03-08.

Sponsored by AZ Sint-Jan AV · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,770
Allocation
Randomized
Ages
45 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies testing colchicine in Coronary Artery Disease — 8 open to participants now, 10 under way, 4 of them phase 3. Colchicine · Coronary Artery Disease.

Planned enrollment
3rd of 26
2,770 · median 175
Started
2024
with 3 others
Phase 3
6 of 26
4 open now
Registered
16th of 26
by date
Lead sponsor
1 of 26
AZ Sint-Jan AV

Among the 26 studies testing colchicine in Coronary Artery Disease, this one is the 3rd largest by planned enrollment, is one of 4 that started in 2024, is one of 6 in phase 3, and was the 16th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

8 of the 26 studies testing colchicine in Coronary Artery Disease are open now, in 3 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About colchicine

Colchicine: first FDA approval 1961 (COLBENEMID), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 45 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing colchicine in Coronary Artery Disease, or all of them as a file.
02

Study summary

The main aim of this trial is to determine whether there are fewer cardiovascular events when patients with coronary artery disease take a low dose of colchicine of 0.5 mg daily on top of optimal standard treatment after treatment with PCI, compared with placebo in combination with optimal standard treatment. More specifically, we aim to investigate the benefits of a daily low dose of colchicine in patients with coronary artery disease after treatment with PCI, to confirm that a daily low dose of colchicine helps prevent additional incidents in coronary artery disease, and to identify a subgroup of patients with CAD who are at increased risk for cardiovascular events and could benefit most from colchicine.

Read the detailed description

This is a prospective, randomised, double-blind, multicenter, placebo-controlled phase III pragmatic superiority trial comparing colchicine 0.5 mg with placebo administered orally once-daily in up to 2770 participants with CAD treated with PCI. Participants will be randomised in a 1:1 ratio to receive either colchicine 0.5 mg or placebo as an adjunct to standard of care. The trial is event driven with trial closure being performed when the targeted number of 566 primary endpoint events has been reached.

Participants will be seen by the site staff 1 month after randomisation and thereafter every 12 months as per standard of care (SOC) and for IMP dispense and compliance, completing questionnaires and outcome event assessment until end of study. After the first month, a telephone visit will be scheduled every 6 months in between two standard of care on-site visits.

03

Conditions studied

  • Coronary Artery Disease

Keywords

  • percutaneous coronary intervention
  • colchicine
04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥45 years.
  2. Coronary artery disease treated with PCI and optimal medical therapy, with at least one additional risk factor (based on SMART):

    1. Age ≥ year
    2. Diabetes mellitus, on treatment or new diagnosis with ≥6.5%
    3. Current smoking
    4. Treated hypertension or lood pressure systolic ≥ 4 mmHg or diastolic ≥ mmHg
    5. Total cholesterol >240 mg/dl untreated, or treated LDL >70 mg/dl
    6. HDL \<40 mg/dl
    7. hsCRP >2 mg/L AND chronic coronary syndrome (CCS)
    8. \<60 ml/min (MDRD)
    9. history of vascular disease:

      • CAD (PCI prior to index, CABG, MI)
      • stroke (ischemic or hemorrhagic)
      • carotid artery revascularisation
      • PAD (revascularisation, ABI \<0.85 at rest, amputation due to atherosclerotic disease)
      • AAA (repair, distal aortic anteroposterior diameter >3.0cm)
  3. Able to be enrolled/randomized between 2 hour and 5 days post PCI.
  4. Written .

Exclusion criteria

Exclusion Criteria:

  1. Women who are pregnant, breastfeeding, or of who are not using an effective method of . Or women who intend to donate oocytes.
  2. Men who plan to father children during the study period or who are unwilling to use effective forms of contraception. Or men who intend to donate sperm.
  3. Any or known intolerance to colchicine.
  4. Chronic use of -or need for- colchicine.
  5. Auto-immune disease or other condition requiring current or planned chronic systemic , or biologic drug targeting the immune system (for example, TNF blockers, anakinra, rituximab, abatacept, tocilizumab etc.).
  6. \<30 mL/min/1.73 m2.
  7. Cirrhosis stadium B and C, or acute severe liver disease
  8. Neuromuscular disease or non-transient CK levels > 5 x (unless due to MI).
  9. History of cancer or lymphoproliferative disease within the last 3 years, other than successfully treated non- cutaneous squamous cell or basal cell carcinoma, or localized cervix carcinoma in situ.
  10. Current or planned use of any strong inhibitor of or p-glycoprotein: macrolide antibiotics (clarithromycin, telithromycin), azole antifungal agents (ketoconazole, voriconazole, fluconazole, itraconazole), cyclosporine, medication (ritonavir, lopinavir, tipranavir, atazanavir, darunavir, indinavir, saquinavir).
  11. Chronic diarrhea, or inflammatory owel disease (Crohn's disease or ulcerative colitis).
  12. Drug or alcohol abuse.
  13. Planned cardiovascular intervention known on the day of screening.
  14. Currently enrolled in another trial.
  15. Considered to be an unsuitable candidate by the investigator.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
2,770 participants (estimated)

Study arms

  • Experimental
    Colchicine

    Colchicine 0.5 mg oral once daily, in addition to SOC

    Drug: Colchicine 0.5 MG Oral Tablet

  • Placebo comparator
    Placebo

    Placebo oral once daily, in addition to SOC

    Drug: Placebo

Interventions

  • DrugColchicineStudies of ColchicineColchicine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Oral intake of 0.5 mg colchicine once daily

  • DrugPlacebo

    Oral intake of matching placebo once daily

06

What researchers measure

Primary outcomes

  1. Time from randomisation to first occurrence of a composite endpoint consisting of: all-cause death, spontaneous (non-procedural) non-fatal myocardial infarction (Type 1, 4B & C), non-fatal stroke, or coronary revascularisation.

    Time frame: 44 months

Secondary outcomes

  1. Time from randomisation to first occurrence of a composite of specific cardiovascular endpoints

    Time from randomisation to first occurrence of a composite of: cardiovascular death, spontaneous (non-procedural) non-fatal myocardial infarction (Type 1, 4B \& C), non-fatal stroke or coronary revascularisation

    Time frame: 44 months

  2. Time from randomisation to first occurrence of a composite of hard endpoints consisting of: all-cause death, spontaneous (non-procedural) non-fatal myocardial infarction (Type 1, 4B & C), non-fatal stroke

    Time frame: 44 months

  3. Time from randomisation to first occurrence of breakdown components of primary endpoint and atherosclerosis-related diseases

    Time from randomisation to first occurrence of: all-cause death, cardiovascular death, spontaneous (non-procedural) non-fatal myocardial infarction (Type 1, 4B \& C), non-fatal stroke, coronary revascularisation, ischemia driven coronary revascularisation, stent thrombosis, peripheral artery revascularisation, transient ischemic attack (TIA) treated with carotid revascularisation

    Time frame: 44 months

  4. Time from randomisation to occurrence of first as well as recurrent endpoints consisting of: all-cause death, spontaneous (non-procedural) non-fatal myocardial infarction (Type 1, 4B & C), non-fatal stroke, or coronary revascularisation.

    Time frame: 44 months

  5. Change from randomisation to year 1 and to end of study of participants reported outcomes (based on ICHOM Standard Set for CAD): Angina Frequency scale

    Change from randomisation to year 1 and to end of study of participants reported outcomes: Seattle Angina Questionnaire (SAQ) Angina Frequency Scale: categorizes angina (chest pain) frequency as following: daily angina (score = 0-30), weekly angina (score = 31-60), monthly angina (score = 61-99), and no angina (score = 100). Higher score indicates better outcome.

    Time frame: 44 months

  6. Change from randomisation to year 1 and to end of study of participants reported outcomes (based on ICHOM Standard Set for CAD): Dyspnea

    Change from randomisation to year 1 and to end of study of participants reported outcomes: Dyspnea (Rose Dyspnea Scale): a four-item questionnaire that assesses a patients' dyspnea level with common activities. One point is assigned to each activity associated with dyspnea. Scores range from 0 to 4. Higher score indicates worse outcome.

    Time frame: 44 months

  7. Change from randomisation to year 1 and to end of study of participants reported outcomes (based on ICHOM Standard Set for CAD): Depression.

    Change from randomisation to year 1 and to end of study of participants reported outcomes: Depression (Patient Health Questionnaire PHQ-2): inquires about the frequency of depressed mood and anhedonia. Scores range from 0 to 6. Higher score indicates worse outcome.

    Time frame: 44 months

  8. Change from randomisation to year 1 and to end of study of participants reported outcomes (based on ICHOM Standard Set for CAD): Health-related quality of life.

    EuroQol five dimensions five level (EQ-5D-5L): consists of a descriptive system of self-perceived health status along fve dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and a visual analogue scale (VAS) which provides a self-rating of the general health status on a scale from 0 (worst imaginable state of health) to 100 (best imaginable state of health).

    Time frame: 44 months

Other outcomes

  1. Change from randomisation to year 1 (and year 2 if available): in hsCRP as a measure of Inflammation.

    Change from randomisation to year 1 (and year 2 if available) in blood lab results from: (high sensitivity) C-reactive protein (mg/dl)

    Time frame: 24 months

  2. Change from randomisation to year 1 (and year 2 if available): in white blood cell count as a measure of Inflammation.

    Change from randomisation to year 1 (and year 2 if available) in blood lab results from: white blood cell count (/μl)

    Time frame: 24 months

  3. Change from randomisation to year 1 (and year 2 if available) in total cholesterol.

    Change from randomisation to year 1 (and year 2 if available) in blood lab results from: total cholesterol (mg/dl)

    Time frame: 24 months

  4. Change from randomisation to year 1 (and year 2 if available) in low density lipoprotein.

    Change from randomisation to year 1 (and year 2 if available) in blood lab results from: low density lipoprotein (LDL) (mg/dl)

    Time frame: 24 months

  5. Change from randomisation to year 1 (and year 2 if available) in high density lipoprotein .

    Change from randomisation to year 1 (and year 2 if available) in blood lab results from: high density lipoprotein (HDL) (mg/dl)

    Time frame: 24 months

  6. Change from randomisation to year 1 (and year 2 if available) in triglycerides.

    Change from randomisation to year 1 (and year 2 if available) in blood lab results from: triglycerides (mg/dl)

    Time frame: 24 months

  7. Change from randomisation to year 1 (and year 2 if available) in kidney function.

    Change from randomisation to year 1 (and year 2 if available) in blood lab results from: estimated glomerular filtration rate (ml/min)

    Time frame: 24 months

07

Study locations

18 of 19 sites recruiting
  • Algemeen Stedelijk Ziekenhuis Campus Aalst
    Aalst, 9300, Belgium
    Recruiting
    • An Roets · Contact
    • Philippe Vanduynhoven, MD · Principal investigator
  • Het Ziekenhuisnetwerk Antwerpen
    Antwerpen, 2020, Belgium
    Recruiting
    • Petra Van Extergem · Contact
    • Paul Vermeersch, MD, PhD · Principal investigator
  • Universitair Ziekenhuis Antwerpen
    Antwerpen, 2650, Belgium
    Recruiting
    • Neda Mohammadi · Contact
    • Frederic De Roeck, MD · Principal investigator
  • Imelda
    Bonheiden, 2820, Belgium
    Recruiting
    • Cris Vissers · Contact
    • Willem Dewilde, MD, PhD · Principal investigator
  • AZ Sint-Jan Brugge-Oostende AV
    Brugge, 8000, Belgium
    Recruiting
    • Sabine Creyf · Contact
    • Ian Buysschaert, MD, PhD · Principal investigator
  • Humani Charleroi
    Charleroi, 6042, Belgium
    Recruiting
    • Asuncion Conde y Bolado · Contact
    • Adel Aminian, MD · Principal investigator
  • Grand Hôpital de Charleroi
    Charleroi, 6060, Belgium
    Not yet recruiting
    • Amandine Jourdan · Contact
    • Frédéric Devroey, MD · Principal investigator
  • Ziekenhuis Oost Limburg
    Genk, 3600, Belgium
    Recruiting
    • Evi Theunissen · Contact
    • Bert Ferdinande, MD · Principal investigator
  • AZ Sint-Lucas & Volkskliniek
    Gent, 9000, Belgium
    Recruiting
    • Nancy Deweerdt · Contact
    • Kurt Hermans, MD · Principal investigator
  • Universitair Ziekenhuis Gent
    Gent, 9000, Belgium
    Recruiting
    • Pieter Vervaet · Contact
    • Frank Timmermans, MD, PhD · Principal investigator
  • Jessa Ziekenhuis
    Hasselt, 3500, Belgium
    Recruiting
    • Julie Bollen · Contact
    • Pascal Vranckx, MD, PhD · Principal investigator
  • Algemeen Ziekenhuis Groeninge
    Kortrijk, 8500, Belgium
    Recruiting
    • Sarah Naessens · Contact
    • Nick Hiltrop, MD · Principal investigator
  • UZ Leuven
    Leuven, 3000, Belgium
    Recruiting
    • Karin Broos · Contact
    • Peter Sinnaeve, MD, PhD · Principal investigator
  • Centre Hospitalier Regional De La Citadelle
    Liège, 4000, Belgium
    Recruiting
    • Valérie Dinraths · Contact
    • Charles Pirlet, MD, PhD · Principal investigator
  • Clinique Saint-Luc Bouge
    Namur, 5004, Belgium
    Recruiting
    • Soon-Ja Collard · Contact
    • François Simon, MD · Principal investigator
  • AZ Delta
    Roeselare, 8800, Belgium
    Recruiting
    • Kathy Vervaecke · Contact
    • Karl Dujardin, MD · Principal investigator
  • AZ Turnhout
    Turnhout, 2300, Belgium
    Recruiting
    • Ellen Van Den Broek · Contact
    • Bert Van Reet, MD · Principal investigator
  • Cliniques Universitaires Saint-Luc
    Woluwe-Saint-Lambert, 1200, Belgium
    Recruiting
    • Joelle De Vriese · Contact
    • Shakeel Kautbally, MD · Principal investigator
  • UCL Mont-Godinne
    Yvoir, 5530, Belgium
    Recruiting
    • Karine Jourdan · Contact
    • Antoine Guédès, MD · Principal investigator
08

References and documents

Publications

  • Fiolet ATL, Opstal TSJ, Mosterd A, Eikelboom JW, Jolly SS, Keech AC, Kelly P, Tong DC, Layland J, Nidorf SM, Thompson PL, Budgeon C, Tijssen JGP, Cornel JH. Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials. Eur Heart J. 2021 Jul 21;42(28):2765-2775. doi: 10.1093/eurheartj/ehab115. Erratum In: Eur Heart J. 2021 Aug 31;42(33):3202. doi: 10.1093/eurheartj/ehab265. PubMed 33769515 ↗
  • Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, Pinto FJ, Ibrahim R, Gamra H, Kiwan GS, Berry C, Lopez-Sendon J, Ostadal P, Koenig W, Angoulvant D, Gregoire JC, Lavoie MA, Dube MP, Rhainds D, Provencher M, Blondeau L, Orfanos A, L'Allier PL, Guertin MC, Roubille F. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med. 2019 Dec 26;381(26):2497-2505. doi: 10.1056/NEJMoa1912388. Epub 2019 Nov 16. PubMed 31733140 ↗
  • Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, The SHK, Xu XF, Ireland MA, Lenderink T, Latchem D, Hoogslag P, Jerzewski A, Nierop P, Whelan A, Hendriks R, Swart H, Schaap J, Kuijper AFM, van Hessen MWJ, Saklani P, Tan I, Thompson AG, Morton A, Judkins C, Bax WA, Dirksen M, Alings M, Hankey GJ, Budgeon CA, Tijssen JGP, Cornel JH, Thompson PL; LoDoCo2 Trial Investigators. Colchicine in Patients with Chronic Coronary Disease. N Engl J Med. 2020 Nov 5;383(19):1838-1847. doi: 10.1056/NEJMoa2021372. Epub 2020 Aug 31. PubMed 32865380 ↗
  • Tong DC, Quinn S, Nasis A, Hiew C, Roberts-Thomson P, Adams H, Sriamareswaran R, Htun NM, Wilson W, Stub D, van Gaal W, Howes L, Collins N, Yong A, Bhindi R, Whitbourn R, Lee A, Hengel C, Asrress K, Freeman M, Amerena J, Wilson A, Layland J. Colchicine in Patients With Acute Coronary Syndrome: The Australian COPS Randomized Clinical Trial. Circulation. 2020 Nov 17;142(20):1890-1900. doi: 10.1161/CIRCULATIONAHA.120.050771. Epub 2020 Aug 29. PubMed 32862667 ↗
  • Dorresteijn JA, Visseren FL, Wassink AM, Gondrie MJ, Steyerberg EW, Ridker PM, Cook NR, van der Graaf Y; SMART Study Group. Development and validation of a prediction rule for recurrent vascular events based on a cohort study of patients with arterial disease: the SMART risk score. Heart. 2013 Jun;99(12):866-72. doi: 10.1136/heartjnl-2013-303640. Epub 2013 Apr 10. PubMed 23574971 ↗
  • Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013 Jan 29;61(4):404-410. doi: 10.1016/j.jacc.2012.10.027. Epub 2012 Dec 19. PubMed 23265346 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Nov 2027, 45 months after the start.

Of 62 phase 3 interventional studies under Coronary Artery Disease, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 58. This study's planned 45 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2023
First posted
Oct 23, 2023
StartActual
Jan 29, 2024
Primary completionEst.
Nov 1, 2027
CompletionEst.
Mar 1, 2028
Last update
Mar 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06095765
Lead sponsor
AZ Sint-Jan AV
Collaborators
University Hospital, Ghent, Belgium Health Care Knowledge Centre
Responsible party
Ian Buysschaert, MD PhD (MD, PhD, Chief investigator, AZ Sint-Jan AV) — Principal investigator
First posted
Oct 23, 2023
Start date
Jan 29, 2024
Primary completion
Nov 1, 2027 (estimated)
Completion
Mar 1, 2028 (estimated)
Last update
Mar 8, 2024

Study contacts

Lisette Van Hove
Contact
Lisette.VanHove@azsintjan.be
+32 50 45 39 07
Hélène De Naeyer
Contact
helene.denaeyer@uzgent.be
+32 9 332 05 05
Ian Buysschaert, MD, PhD
principal investigator · ian.buysschaert@azsintjan.be

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Colchicine

Start the discussion